Nektar Therapeutics (NKTR) concluded trading on Wednesday at a closing price of $1.29, with 4.9 million shares of worth about $6.32 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 153.04% during that period and on April 10, 2024 the price saw a gain of about 3.20%. Currently the company’s common shares owned by public are about 191.38M shares, out of which, 178.15M shares are available for trading.
Stock saw a price change of 24.04% in past 5 days and over the past one month there was a price change of 55.10%. Year-to-date (YTD), NKTR shares are showing a performance of 128.32% which increased to 52.99% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.41 but also hit the highest price of $1.47 during that period. The average intraday trading volume for Nektar Therapeutics shares is 1.97 million. The stock is currently trading 31.70% above its 20-day simple moving average (SMA20), while that difference is up 57.32% for SMA50 and it goes to 104.14% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Nektar Therapeutics (NASDAQ: NKTR) currently have 191.38M outstanding shares and institutions hold larger chunk of about 65.28% of that.
The stock has a current market capitalization of $236.87M and its 3Y-monthly beta is at 0.87. It has posted earnings per share of -$1.46 in the same period. It has Quick Ratio of 6.14 while making debt-to-equity ratio of 1.76. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NKTR, volatility over the week remained 17.52% while standing at 10.03% over the month.
Analysts are in expectations that Nektar Therapeutics (NKTR) stock would likely to be making an EPS of -$0.19 in the current quarter, while forecast for next quarter EPS is -$0.19 and it is -$0.71 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.22 which is -$0.17 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.73 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 38.97% while it is estimated to increase by 19.49% in next year.
On May 10, 2023, Jefferies Upgrade their recommendations, while on February 24, 2023, Jefferies Downgrade their ratings for the stock with a price target of $1.50. Stock get an Underweight rating from JP Morgan on August 08, 2022.
